In vivo activities of peptidic prodrugs of novel aminomethyl tetrahydrofuranyl-1β-methylcarbapenems

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 460-464

  Weiss, William J ^a   Mikels, Susan M ^a   Petersen, Peter J ^a   Jacobus, Nilda V ^a   Bitha, Panayota ^a   Lin, Yang I ^a   Testa, Raymond T ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINOMETHYL 3 TETRAHYDROFURANYLTHIO) 6 (1 HYDROXYETHYL) 1BETA METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; 2 (5 AMINOMETHYL 3 TETRAHYDROFURANYLTHIO) 6 (1 HYDROXYETHYL) 1BETA METHYL 1 CARBAPEN 2 EM 3 CARBOXYLIC ACID; ALANINE; CARBAPENEM DERIVATIVE; ISOLEUCINE; PHENYLALANINE; PRODRUG; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MIXTURE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEREOCHEMISTRY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033012755     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.460     Document Type: Article

References (20)

1. Agouridas, C., A. Bonnefoy, and J. Chantot. 1995. In vivo antibacterial activity of RU 004, a novel ketolide highly active against respiratory pathogens, abstr. F171, p. 143. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Finney, D. 1971. Probit analysis, 3rd ed. Cambridge University Press, London, United Kingdom.
3. Fish, D., and T. Singletary. 1997. Meropenem, a new carbapenem antibiotic. Pharmacotherapy 17:644-699.
4. Ford, C., J. Hamel, D. Wilson, J. Moerman, D. Stapert, R. Yancey, D. Hutchinson, M. Barbachyn, and S. Brickner. 1996. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. 40:1508-1513.
5. Fukuoka, T., S. Ohya, Y. Ulsui, H. Domon, T. Takenouchi, T. Koga, N. Masuda, H. Kawada, M. Kakuta, M. Kubota, C. Ishii, E. Sakagawa, T. Harasaki, A. Hirasawa, T. Abe, H. Yasuda, M. Iwata, and S. Kuwahara. 1997. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. Antimicrob. Agents Chemother. 41:2652-2663.
6. Klugman, K., F. Goldstein, S. Kohno, and F. Baquero. 1997. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin. Microbiol. Infect. 3:S48-S60.
7. Lin, Y.-L. P. Bitha, S. Sakya, Z. Li, S. Lang, Y. Yang, N. Bhachech, W. Weiss, P. Petersen, N. Jacobus, K. Bush, and R. Testa. 1997. Peptidic prodrugs of novel aminomethyl-THF 1β-methylcarbapenems. Bioorg. Med. Chem. Lett. 7:1665-1670.
8. Lin, Y.-I., P. Bitha, S. Sakya, Z. Li, T. Strohmeyer, S. Lang, Y. Yang, N. Bhachech, W. Weiss, P. Petersen, N. Jacobus, K. Bush, and R. Testa. 1997. Mono and bis double ester prodrugs of novel aminomethyl-THF 1β-methylcarbapenems. Bioorg. Med. Chem. Lett. 7:1811-1816.
9. Lin, Y.-I., P. Bitha, S. Sakya, T. Strohmeyer, Z. Li, V. Lee, S. Lang, Y. Yang, N. Bhachech, W. Weiss, P. Petersen, N. Jacobus, K. Bush, R. Testa, and F. Tally. 1997. Synthesis and structure activity relationships of novel THF 1β methylcarbapenems. Bioorg. Med. Chem. Lett. 7:1671-1676.
10. Murray, B. 1991. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J. Infect. Dis. 163:1185-1194.
11. Murray, B. 1992. Problems and dilemmas of antimicrobial resistance. Pharmacotherapy, 12(6 Pt 2):86S-93S.
12. Nagano, R., K. Shibata, T. Naito, A. Fuse, K. Asano, T. Hashizume, and S. Nakagawa. 1997. Therapeutic efficacy of BO-3482, a novel dithiocarbamate carbapenem, in mice infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2278-2281.
13. Perry, C., and R. Brogden. 1996. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 52:125-158.
14. Shlaes, D., B. Binczewski, and L. Rice. 1993. Emerging antimicrobial resistance and the immunocompromised host. Clin. Infect. Dis. 17(Suppl. 2): S527-S536.
15. Spangler, S., G. Lin, M. Jacobs, and P. Applebaum. 1997. Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 41:2173-2176.
16. Tanaka, M., M. Hohmura, T. Nishi, K. Sato, and I. Hayakawa. 1997. Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640. Antimicrob. Agents Chemother. 41:1260-1268.
17. Tsuji, M., Y. Ishi, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1995. In vitro and in vivo antibacterial activity of S-1090, a new oral cephalosporin. Antimicrob. Agents Chemother. 39:2544-2551.
18. Tsuji, M., Y. Ishi, A. Ohno, S. Miyazaki, and K. Yamaguchi. 1998. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob. Agents Chemother. 42:94-99.
19. Weiss, W., Y. Yang, P. Petersen, A. Shelofsky, K. Bush, N. Jacobus, P. Bitha, Y.-I. Lin, R. Testa, and F. Tally. 1994. In vitro antibacterial activity and β-lactamase stability of novel THF carbapenems, abstr. F74, p. 128. In Programs and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. Washington, D.C.
20. Wise, R., J. Andrews, L. Ros, J. Child, and D. Mortiboy. 1997. A study to determine the pharmacokinetics and inflammatory fluid penetration of two doses of a solid formulation of the hexetil prodrug of a trinem, sanfetrinem (GV 104326). Antimicrob. Agents Chemother. 41:1761-1764.